When it comes to managing chronic conditions and rare disease, the cost of treatment can be astronomical.
When it comes to managing chronic conditions and rare disease, the cost of treatment can be astronomical. Fran Gregory, PharmD, MBA, director of specialty pharmacy, Humana Pharmacy Solutions, offered her solutions to PBMI attendees, saying there are a variety of options to manage the rising costs of specialty drugs. Dr Gregory suggested that savings opportunities for providers, payers, and patients must include considerations such as utilization management, cost-effective delivery channels, and increasing adherence among members.
Dr Gregory says that utilization and inflation are related. Because there is a small population afflicted with chronic illness and rare disease, the cost to produce these prescription drugs is spread out among a smaller amount of patients. As inflation increases, so does the cost. For instance, one multiple sclerosis drug cost about $1500 in 2007. Today that same drug costs $4600.
She went on to describe that when managing conditions like chronic myeloid leukemia (CML), adherence greater than 90% was more than often a result of major molecular response or complete molecular response system requirements. She said strong adherence ensures that the prices of costlier specialty drugs do not go wasted—providers want to make sure that patients are taking medications as prescribed to order to improve outcomes.
To drive this level of adherence (>90 %) requires a system of alignment. The pharmacy benefit must align with the specialty pharmacy, and both must align with the medical benefit. Dr Gregory says aligning pharmacy and medical policy is important to lowering costs not only in specialty drugs but on high-priced assessments such as pharmacogenomic tests.
Other conditions such as rheumatoid arthritis and hepatitis C also require the development of better clinical management programs to control costs and drive adherence. A better management program would let patients know what to expect. In hepatitis C, for example, as more drug classes are developed, more leverage and options for managing the condition are provided. Dr Gregory says challenges lie ahead, but “We are gaining coverage in this space.”
Overall, she says, there is a 3-stage approach to making specialty drugs affordable: aligning the strategic management of medical, pharmacy, and special pharmacy.
Stephanie Holliday, PharmD, senior director of clinical operations for AcariaHealth, who co-presented with Dr Gregory, said there are trending outcomes in the management of MS with the newly approved oral agent, Tecfidera. AcariaHealth’s care management program utilizes such treatments to produce outcomes that provide cost savings. Underscoring Dr Gregory’s focus on medication adherence, she suggests that collaboration through patient portals and Web-based tools like AricaConnect is vital.
The Pivotal Role of Payers in Improving Health Equity, Maternal Health Care in the US
March 26th 2024A presentation at the Greater Philadelphia Business Coalition on Health's 2024 Women’s Health Summit discussed how payers, including employers and public entities, can strategically influence health care purchasing to prioritize maternal health and equity.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Dupilumab Considered Safe, Effective Treatment for Adolescent, Adult Patients With AD
March 20th 2024These posters both used the GLOBOSTAD study, which demonstrated through patient and physician assessments that dupilumab is a safe and effective treatment for adolescent and adult patients with atopic dermatitis (AD).
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Racial Variations in Cardiovascular Outcomes Found in Hidradenitis Suppurativa Study
March 19th 2024Based on the findings, investigators acknowledged the critical need to consider racial differences when assessing patients with hidradenitis suppurativa. Health care providers should be vigilant in addressing cardiovascular risk factors in this population, recognizing and addressing racial disparities that may impact disease management.
Read More